CNBC June 18, 2024
Annika Kim Constantino, Ashley Capoot

Good morning! More U.S. employers are covering a buzzy class of medications called GLP-1s for weight loss, a survey found.

Roughly one-third of employer health plans in the U.S. said they are covering GLP-1 drugs like Novo Nordisk‘s Ozempic and Wegovy for both diabetes and weight loss, up from 26% last year.

GLP-1 drugs for weight loss also grew as a portion of employers’ overall annual medical claims spending, making up nearly 9% in 2024 compared to roughly 7% the year prior.

That’s according to the survey released Thursday by a nonprofit organization, the International Foundation of Employee Benefit Plans, which includes more than 33,000 member companies or public institutions. The survey was conducted in May on...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Employer, Insurance, Patient / Consumer, Pharma / Biotech, Provider
The Pandemic Proved That Remote Leadership Works
More than 65 Organizations Call on Workplaces to Provide Comprehensive Obesity Care Coverage
The state of AI: How organizations are rewiring to capture value
To reduce healthcare costs, address chronic conditions
Why Leaders Must Rethink Customer Experience Amid Continued AI Investment

Share This Article